Facebook Instagram X-twitter Linkedin Youtube Spotify Apple

Duchenne News Tags: Catalyst Pharmaceuticals

Search
Tags
Tags
Antisense Therapeutics Astellas Pharma Avidity Biosciences BioMarin Pharmaceuticals Capricor Therapeutics Catalyst Pharmaceuticals Dyne Therapeutics Edgewise Therapeutics Entrada Therapeutics FDA FibroGen Italfarmaco ITF Therapeutics NS Pharma PepGen Percheron Therapeutics Pfizer Pliant Therapeutics Precision Biosciences PTC Therapeutics REGENXBIO Roche Santhera Sarepta Therapeutics Satellos Bioscience Solid Biosciences Upsher-Smith Wave Life Sciences
March 13, 2024

Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy

Following the FDA approval on October 26, 2023, AGAMREE is now available by prescription and dispensed throughout the United States through a specialty pharmacy network.
Read More
October 30, 2023

Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals

Catalyst shares that the U.S. Food and Drug Administration (FDA) approved a new steroid treatment for Duchenne muscular dystrophy.
Read More

Jett Foundation’s Silver Soirée
Thursday, June 11, 2026 | 5:30PM
Granite Links | Quincy, MA